Status:

COMPLETED

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Lead Sponsor:

Janssen Research & Development, LLC

Conditions:

Breast Cancer

Neoplasm Metastasis

Eligibility:

FEMALE

18-99 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to assess the impact on tumor progression as evaluated by progression-free survival (PFS) of epoetin alfa plus standard supportive care as compared with standard supportiv...

Detailed Description

Anemia is a common complication of the treatment of metastatic breast cancer and is related to the effects of chemotherapy and to chronic disease itself. This is a randomized, open-label, multicenter,...

Eligibility Criteria

Inclusion

  • Histologically confirmed (e.g., slide of tissue) breast cancer
  • HER2/NEU positive or negative
  • Clinical evidence of metastasis (e.g., biopsy) with at least 1 measurable metastatic (M1) lesion prior to starting the current chemotherapy
  • Received 1st and 2nd line chemotherapy
  • Hemoglobin (Hb) \<= 11g/dL at the time of randomization
  • planned to receive at least 2 more cycles of chemotherapy
  • Life expectancy \> 6 months
  • Eastern Cooperative Oncology Group score 0 or 1
  • At least 18 years old using effective birth control or surgically sterile or postmenopausal for 1 year

Exclusion

  • Active second cancer
  • no recent history of clinically relevant thrombovascular event
  • Current treatment with anticoagulants
  • Brain metastasis or CNS involvement
  • Anemia secondary to another cause
  • Recent (within prior 1 months) use of an ESA
  • Patient pregnant or breast feeding
  • Progressive disease during adjuvant/neoadjuvant chemotherapy
  • Rapidly progressive or life-threatening metastatic disease
  • Concomitant endocrine therapy
  • Patient in whom the only site of metastasis was local and was successfully treated surgically.

Key Trial Info

Start Date :

March 2 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 31 2017

Estimated Enrollment :

2098 Patients enrolled

Trial Details

Trial ID

NCT00338286

Start Date

March 2 2006

End Date

January 31 2017

Last Update

March 19 2018

Active Locations (174)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 44 (174 locations)

1

Anaheim, California, United States

2

Gainesville, Florida, United States

3

Miami, Florida, United States

4

New Port Richey, Florida, United States